# Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

> **NCT01524289** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 306 (actual)

## Conditions studied

- Hyperlipoproteinemia Type II
- Hypercholesterolemia, Familial

## Interventions

- **DRUG:** Anacetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01524289
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-03
- **Primary completion:** 2014-02-12
- **Final completion:** 2018-11-13
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2019-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524289, "Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01524289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*